A phase I/II study of concurrent weekly docetaxel (Taxotere), androgen ablation, and adaptive external beam radiotherapy for localized high-risk adenocarcinoma of the prostate.
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Docetaxel (Primary) ; Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jun 2011 Planned end date changed from 1 Jun 2009 to 1 Aug 2012 as reported by ClinicalTrials.gov.
- 08 Nov 2010 Status changed from recruiting to active, no longer recruiting.